The effects of semaglutide are to increase insulin release, reduce glucagon release, delay gastric emptying, and reduce appetite
Obese women (BMI, 25-30) are much more likely to have GLP-1 side-effects, including heartburn and acid reflux reflux (range 70%-90%)
And then in that way, the effects of these medications can be synergistic with the procedural interventions we have to treat atrial fibrillation, and that could lead to even more successful results and greater freedom from atrial fibrillation. For more information: Kenneth C
External resources New England Journal of Medicine: Tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2 trial) PMC: Switching between GLP-1 receptor agonists, rationale and practical guidance Endocrine Practice: Switching to tirzepatide from GLP-1 receptor agonists, clinical expectations PMC: The risk of vestibular disorders with semaglutide and tirzepatide In case I do not see you, good afternoon, good evening, and good night